HCmed Innovations Co., Ltd., a contract development and manufacturing organization (CDMO), appointed Gunilla Petersson, Ph.D. chief scientific officer (CSO). In her role as CSO, Petersson will contribute to the company's strategic business development, while providing professional advice with regards to combination product development.
AeroRx Therapeutics, a spin-off of US-based iPharma Lab's inhalation business and Taiwan-based startup HCmed Innovations have initiated a collaboration, introducing a LABA/LAMA (long-acting muscarinic antagonist/long-acting beta agonist) combination solution for delivery with a breath-actuated nebulizer.
TAIPEI, March 6, 2022 /PRNewswire/ -- HCmed Innovations, Co., Ltd. (HCmed) announced that it has formed a strategic alliance with Formosa Laboratories, Inc. (TPEx: 4746) and Formosa Pharmaceuticals, Inc. (TPEx: 6838) to expand its business in the inhalation treatment field, providing contract development and manufacturing services. By integrating HCmed's vibrating mesh nebulizers, Formosa Laboratories' drug development and manufacturing capabilities, and Formosa Pharmaceuticals' APNT nanotechnology platform, the three parties are expected to become a one-stop shop in the biopharmaceutical industry as a full-service contract development and manufacturing organization (CDMO).